Literature DB >> 2430119

[Cisplatin, vinblastine and bleomycin (PVB) combination chemotherapy in the treatment of intracranial malignant germ cell tumors--a preliminary report of a phase II study--The Japanese Intracranial Germ Cell Tumor Study Group].

Y Matsukado, H Abe, R Tanaka, T Kobayashi, J Yamashita, A Nishimoto, Y Ushio, K Sato, M Matsutani, K Takakura.   

Abstract

Cisplatin, vinblastine and bleomycin (PVB) combination chemotherapy was undertaken in 30 patients with primary intracranial malignant germ cell tumors in 11 neurosurgical clinics. The response rate of 17 evaluable patients with nonrecurrent tumors was 64.7% (eight CR and three PR), and that in eight patients with recurrent tumors was 50% (two CR and two PR). The one-year and two-year survival rates were 76.2% and 67.7%, respectively, which are better than the treatment results by radiation therapy alone, i.e., 69.8% and 46.5%. These findings suggest that PVB therapy is effective for intracranial malignant germ cell tumors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2430119

Source DB:  PubMed          Journal:  Gan No Rinsho        ISSN: 0021-4949


  10 in total

1.  Treatment results and prognostic factors for intracranial nongerminomatous germ cell tumors: single institute experience.

Authors:  I-Chun Lai; Tai-Tong Wong; Cheng-Ying Shiau; Yu-Wen Hu; Donald Ming-Tak Ho; Kai-Ping Chang; Wan-Yuo Guo; Feng-Chi Chang; Muh-Lii Liang; Yi-Yen Lee; Hsin-Hung Chen; Sang-Hue Yen; Yi-Wei Chen
Journal:  Childs Nerv Syst       Date:  2015-03-08       Impact factor: 1.475

2.  Significance of human chorionic gonadotropin as a predictor of resistance to standard chemo-radiotherapy for pure germinoma.

Authors:  Akihiro Inoue; Takanori Ohnishi; Shohei Kohno; Shiro Ohue; Shinji Iwata; Shirabe Matsumoto; Masahiro Nishikawa; Saya Ozaki; Yawara Nakamura; Yosuke Mizuno; Riko Kitazawa; Takeharu Kunieda
Journal:  Neurosurg Rev       Date:  2017-08-18       Impact factor: 3.042

3.  Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study.

Authors:  Antonio Silvani; Marica Eoli; Andrea Salmaggi; Elena Lamperti; Laura Fariselli; Ida Milanesi; Giovanni Broggi; Carlo Lazzaro Solero; Sergio Giombini; Amerigo Boiardi
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

4.  Combined chemotherapy and radiation therapy for CNS germ cell tumors--the Japanese experience.

Authors:  M Matsutani
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

5.  Survival outcomes, hematologic complications and growth impairment after sequential chemoradiotherapy in intracranial NGGCTs: a retrospective study.

Authors:  Lei Wen; Juan Li; Mingyao Lai; Zhaoming Zhou; Qingjun Hu; Guanhua Deng; Changguo Shan; Ruyu Ai; Hainan Li; Ming Lu; Liang Zhang; Taihua Wu; Dan Zhu; Yuanyuan Chen; Longhua Chen; Linbo Cai; Cheng Zhou
Journal:  Strahlenther Onkol       Date:  2021-10-21       Impact factor: 3.621

6.  Prognosis of intracranial germ cell tumours: effectiveness of chemotherapy with cisplatin and etoposide (CDDP and VP-16).

Authors:  J Yoshida; K Sugita; T Kobayashi; K Takakura; N Shitara; M Matsutani; R Tanaka; H Nagai; H Yamada; J Yamashita
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

7.  CT and MRI features of intracranial germ cell tumors.

Authors:  T Fujimaki; M Matsutani; N Funada; T Kirino; K Takakura; O Nakamura; A Tamura; K Sano
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  Current advances in the diagnosis and management of intracranial germ cell tumors.

Authors:  Casilda Balmaceda; Jonathan Finlay
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

9.  Germ cell tumor in the hypothalamo-neurohypophysial region: clinical features and treatment.

Authors:  S Nishio; T Inamura; I Takeshita; M Fukui; K Kamikaseda
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

10.  Vinblastine monotherapy induction prior to radiotherapy for patients with intracranial germinoma during the COVID-19 pandemic.

Authors:  Matthew J Murray; Rafael Moleron; Jennifer Adamski; Martin English; G A Amos Burke; Justin Cross; Thankamma Ajithkumar; Sara Stoneham; James C Nicholson
Journal:  Pediatr Blood Cancer       Date:  2021-09-14       Impact factor: 3.167

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.